Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|June 10, 2020
First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelinesKate El Bouzidi, Sophie Jose, Andrew N Phillips, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2017
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan AfricaRuth L Goodall, David T Dunn, Peter Nkurunziza, et al.
HIV Clinical Trials|October 18, 2017
HIV prevention trial design in an era of effective pre-exposure prophylaxisAmy Cutrell, Deborah Donnell, David T Dunn, et al.
AIDS Research and Human Retroviruses|May 9, 2015
Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase InhibitorsJonathan K Kayondo, Nicaise Ndembi, Chris M Parry, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UKJean L Mbisa, Juan Ledesma, Peter Kirwan, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2013
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyDavid I Dolling, David T Dunn, Katherine A Sutherland, et al.
The Journal of Antimicrobial Chemotherapy|November 19, 2016
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UKKate El Bouzidi, Ellen White, Jean L Mbisa, et al.
AIDS (London, England)|July 27, 2016
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapyWolfgang Stöhr, David T Dunn, Alejandro Arenas-Pinto, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2017
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIsErasmus Smit, Ellen White, Duncan Clark, et al.
Journal of Viral Hepatitis|April 4, 2020
High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxisMonica Desai, Ellen White, Nina Vora, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|June 10, 2020
First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelinesKate El Bouzidi, Sophie Jose, Andrew N Phillips, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2017
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan AfricaRuth L Goodall, David T Dunn, Peter Nkurunziza, et al.
HIV Clinical Trials|October 18, 2017
HIV prevention trial design in an era of effective pre-exposure prophylaxisAmy Cutrell, Deborah Donnell, David T Dunn, et al.
AIDS Research and Human Retroviruses|May 9, 2015
Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase InhibitorsJonathan K Kayondo, Nicaise Ndembi, Chris M Parry, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UKJean L Mbisa, Juan Ledesma, Peter Kirwan, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2013
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyDavid I Dolling, David T Dunn, Katherine A Sutherland, et al.
The Journal of Antimicrobial Chemotherapy|November 19, 2016
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UKKate El Bouzidi, Ellen White, Jean L Mbisa, et al.
AIDS (London, England)|July 27, 2016
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapyWolfgang Stöhr, David T Dunn, Alejandro Arenas-Pinto, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2017
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIsErasmus Smit, Ellen White, Duncan Clark, et al.
Journal of Viral Hepatitis|April 4, 2020
High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxisMonica Desai, Ellen White, Nina Vora, et al.
Pageof 8